Thu, May 8, 11:30 AM (15 days ago)
**Akebia Therapeutics, Inc. (AKBA) Q1 2025 Financial Summary** **Revenue:** - **Total Revenue:** $57.3 million, up 76% from $32.6 million in Q1 2024. - **Product Revenue:** $55.8 million, up 80% from $31.0 million in Q1 2024. - **Vafseo:** $12.0 million (newly launched in Q1 2025). - **Auryxia:** $43.8 million, up 41% from $31.0 million in Q1 2024. - **License, Collaboration, and Other Revenue:** $1.5 million, down 3% from $1.6 million in Q1 2024. **Expenses:** - **Cost of Goods Sold:** $7.6 million, up 194% from $2.6 million in Q1 2024. - **Cost of Product and Other Revenue:** $7.6 million, up 194% from $2.6 million in Q1 2024. - **Amortization of Intangible Asset:** $0, down 100% from $9.0 million in Q1 2024. - **Operating Expenses:** $36.2 million, up 1% from $35.9 million in Q1 2024. - **Research and Development:** $9.8 million, up 0.2% from $9.7 million in Q1 2024. - **Selling, General, and Administrative:** $25.7 million, up 1% from $25.4 million in Q1 2024. - **License:** $0.7 million, down 1% from $0.7 million in Q1 2024. - **Restructuring:** $0, down 100% from $0.1 million in Q1 2024. - **Net Income (Loss):** $6.1 million, up 234% from a loss of $18.0 million in Q1 2024. **Cash Flow:** - **Net Cash Used in Operating Activities:** $13.6 million, down 30% from $19.4 million in Q1 2024. - **Net Cash Provided by (Used in) Investing Activities:** $0.2 million, up from $0 in Q1 2024. - **Net Cash Provided by Financing Activities:** $74.9 million, up 313% from $18.5 million in Q1 2024. - **Cash, Cash Equivalents, and Restricted Cash:** $115.1 million, up 159% from $43.6 million in Q1 2024. **Key Metrics:** - **Cash and Cash Equivalents:** $113.4 million, up 119% from $51.9 million in Q1 2024. - **Restricted Cash:** $1.7 million, up 1% from $1.7 million in Q1 2024. - **Total Assets:** $310.2 million, up 41% from $220.7 million in Q1 2024. - **Total Liabilities:** $285.6 million, up 30% from $219.9 million in Q1 2024. - **Total Stockholders' Equity:** $24.6 million, up from a deficit of $49.2 million in Q1 2024. **Debt:** - **Total Debt:** $46.5 million, up 20% from $38.7 million in Q1 2024. - **Interest Expense:** $7.8 million, up 210% from $2.5 million in Q1 2024. **Stock:** - **Shares Outstanding:** 261.6 million, up 17% from 224.8 million in Q1 2024. - **Net Income (Loss) per Share:** $0.03, up from a loss of $0.09 in Q1 2024. **Product Performance:** - **Vafseo:** Launched in Q1 2025, contributing $12.0 million in revenue. - **Auryxia:** Revenue up 41% to $43.8 million, despite loss of exclusivity in March 2025. **Financial Outlook:** - **Cash Resources:** Expected to be sufficient to fund operations for at least 12 months from the filing date. - **Future Financing:** May seek additional public or private equity, enter into new debt transactions, or explore strategic transactions. **Risks and Uncertainties:** - **Regulatory:** Potential delays or denials in marketing approvals, post-marketing requirements, and changes in healthcare policies. - **Competition:** Competition from existing and new therapies, including generics and biosimilars. - **Operational:** Dependence on third-party manufacturers, distributors, and collaborators. - **Financial:** Need for additional financing, potential dilution of shareholders, and impact of healthcare reform. **Future Operations:** - **Product Development:** Continued development of Vafseo and Auryxia, including potential label expansions. - **Commercialization:** Focus on increasing market share and expanding product offerings. - **Strategic Transactions:** Potential acquisitions, collaborations, or licensing agreements to enhance product portfolio.